Taiwan Stock Exchange · Healthcare
Chunghwa Chemical Synthesis & Biotech stock from India: price, numbers and tax
Chunghwa Chemical Synthesis & Biotech (1762) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Chunghwa Chemical Synthesis & Biotech at a glance
- Price
- NT$34.70-NT$0.20 (0.57%)
- Market cap
- NT$2.67B
- Day range
- NT$34.50 – NT$34.95
- P/E
- -37.31
- Dividend yield
- None
- Volume
- 1.00K
- 1 month
- +2.97%
- 6 months
- +23.49%
- YTD
- +41.63%
- 1 year
- +35.81%
- 5 years
- -48.44%
Chunghwa Chemical Synthesis & Biotech statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$804.9M | NT$1.3B | NT$2.1B | NT$2.1B | NT$1.9B |
| Gross profit | −NT$8.9M | NT$394.3M | NT$757.3M | NT$961.8M | NT$949.4M |
| Operating income | −NT$319.5M | NT$6.3M | NT$280.8M | NT$574.7M | NT$519.3M |
| Net income | −NT$243.8M | NT$53.0M | NT$264.9M | NT$465.9M | NT$400.8M |
| Earnings per share | −NT$4.39 | NT$0.70 | NT$3.42 | NT$6.01 | NT$5.17 |
| EBITDA | −NT$47.6M | NT$277.7M | NT$545.9M | NT$743.7M | NT$651.3M |
| Total assets | NT$4.3B | NT$4.8B | NT$5.2B | NT$4.6B | NT$4.4B |
| Total debt | NT$805.9M | NT$858.2M | NT$1.2B | NT$604.5M | NT$753.6M |
| Cash and short-term investments | NT$216.4M | NT$222.3M | NT$269.6M | NT$300.6M | NT$195.3M |
| Shareholders' equity | NT$3.1B | NT$3.4B | NT$3.4B | NT$3.2B | NT$2.9B |
| Operating cash flow | NT$142.6M | NT$467.7M | −NT$66.3M | NT$733.8M | NT$219.2M |
| Free cash flow | NT$80.3M | NT$363.0M | −NT$517.8M | NT$357.6M | −NT$186.3M |
| Capital expenditure | −NT$62.3M | −NT$104.7M | −NT$450.0M | −NT$376.2M | −NT$405.5M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Hcmed | 6934.TWO | $155.00 | $5.58B |
| GlycoNex Incorporation | 4168.TWO | $22.00 | $2.48B |
| Genomics BioSci & Tech. | 4195.TWO | $29.45 | $2.36B |
| Sunny Pharmtech | 6676.TWO | $10.25 | $1.74B |
| Advagene Biopharma | 6709.TWO | $25.00 | $1.71B |
| Greenyn Biotechnology | 6846.TWO | $58.40 | $1.58B |
| NaviFUS | 6872.TWO | $20.50 | $1.45B |
| InnoPharmax | 4172.TWO | $10.10 | $1.19B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Chunghwa Chemical Synthesis & Biotech from India
What Chunghwa Chemical Synthesis & Biotech does
Based in New Taipei City, Taiwan, Chunghwa Chemical Synthesis & Biotech Co., Ltd., established in 1964 and previously known as China Chemical Synthesis Industry Co., Ltd., specializes in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's market reach includes Taiwan and the United States. Chunghwa Chemical Synthesis & Biotech operates in the Medical - Pharmaceuticals industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Chunghwa Chemical Synthesis & Biotech shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.